Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APR-1051 in Patients With Advanced Solid Tumors

NCT06260514 is registered in ClinicalTrials.gov with Aprea Therapeutics as lead sponsor.

NCT NCT06260514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06260514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APR-1051 in Patients With Advanced Solid Tumors
Lead sponsor
Aprea Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
June 13, 2024
Completion date
June 30, 2028
Enrollment
90 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor